| 前收市價 | 26.02 |
| 開市 | 26.64 |
| 買盤 | 0.00 x 0 |
| 賣出價 | 0.00 x 0 |
| 今日波幅 | 26.64 - 26.64 |
| 52 週波幅 | 25.04 - 32.76 |
| 成交量 | |
| 平均成交量 | 8,546 |
| 市值 | 42.069B |
| Beta 值 (5 年，每月) | 0.54 |
| 市盈率 (最近 12 個月) | 45.93 |
| 每股盈利 (最近 12 個月) | 0.58 |
| 業績公佈日 | 2024年7月31日 |
| 遠期股息及收益率 | 1.26 (4.73%) |
| 除息日 | 2024年9月27日 |
| 1 年預測目標價 | 無 |
Investor's Business DailyCatalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly has watched Catalyst Pharmaceuticals transform. Now, as the company's new CEO, he has some metamorphic ideas of his own.
BenzingaJapan's Takeda Pharma Outlines $900M Overhaul To Boost Growth, As 2023 Profit Fall Over 50%
On Thursday, Japan’s drugmaker Takeda Pharmaceutical Company Limited (NYSE:TAK) announced a restructuring after the company reported a fiscal year 2023 net profit of 144 billion yen (around $954 million), down 54.6% Y/Y. Core net profit fell 12.6% (down 15% at constant currency) to 756.8 billion yen. Takeda said it will incur restructuring costs of about 140 billion yen in fiscal year 2024 as part of a plan to optimize its workforce, cut costs, and strengthen technology. Revenue was 4.26 trillio
ZacksDown -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Takeda Pharmaceutical Co. (TAK) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
